Payment overview · 2025
General Payments
$33.95
2 reported records · 2 companies
Healthcare provider profile · identity verified
Anil Kumar Puri, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · AUGUSTA, GA · NPI 1629166335
Verified facts
What the public records show
CMS Open Payments records show Anil Kumar Puri, M.D. received $33.95 in general payments during 2025 across 2 reported records.
GENZYME CORPORATION accounted for 51.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 316 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $17.49 | 51.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.46 | 48.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $33.95 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 316 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
62 | 61 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
38 | 26 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
316 | 89 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 563 | 181 |
| Amlodipine Besylate | Amlodipine Besylate | 509 | 166 |
| Pantoprazole Sodium | Pantoprazole Sodium | 332 | 112 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 316 | 89 |
| Losartan Potassium | Losartan Potassium | 287 | 83 |
| Atorvastatin Calcium | Atorvastatin Calcium | 282 | 88 |
| Fluticasone Propionate | Fluticasone Propionate | 252 | 104 |
| Metformin Hcl | Metformin Hcl | 211 | 63 |
| Famotidine | Famotidine | 208 | 74 |
| Omeprazole | Omeprazole | 192 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 188 | 71 |
| Furosemide | Furosemide | 188 | 71 |
| Levothyroxine Sodium | Levothyroxine Sodium | 183 | 67 |
| Montelukast Sodium | Montelukast Sodium | 183 | 54 |
| Lisinopril | Lisinopril | 172 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 159 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 153 | 57 |
| Azelastine Hcl | Azelastine Hcl | 151 | 63 |
| Gabapentin | Gabapentin | 150 | 48 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 147 | 44 |
| Sertraline Hcl | Sertraline Hcl | 135 | 42 |
| Methylprednisolone | Methylprednisolone | 134 | 108 |
| Potassium Chloride | Potassium Chloride | 130 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 125 | 42 |
| Hydralazine Hcl | Hydralazine Hcl | 119 | 37 |
| Farxiga | Dapagliflozin Propanediol | 118 | 29 |
| Jardiance | Empagliflozin | 110 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 108 | 35 |
| Carvedilol | Carvedilol | 95 | 29 |
| Eliquis | Apixaban | 94 | 26 |
| Ozempic | Semaglutide | 94 | 28 |
| Glipizide Er | Glipizide | 92 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 28 |
| Alprazolam | Alprazolam | 75 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 74 | 29 |
| Trazodone Hcl | Trazodone Hcl | 72 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 19 |
| Ezetimibe | Ezetimibe | 68 | 22 |
| Simvastatin | Simvastatin | 65 | 21 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 62 | 61 |
| Azithromycin | Azithromycin | 60 | 37 |
| Pioglitazone Hcl | Pioglitazone Hcl | 59 | 18 |
| Prednisone | Prednisone | 59 | 34 |
| Breo Ellipta | Fluticasone/Vilanterol | 56 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 55 | 18 |
| Meloxicam | Meloxicam | 53 | 22 |
| Tramadol Hcl | Tramadol Hcl | 52 | 21 |
| Levofloxacin | Levofloxacin | 51 | 49 |
| Mounjaro | Tirzepatide | 50 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 47 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 45 | 43 |
| Allopurinol | Allopurinol | 41 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | 12 |
| Glipizide | Glipizide | 38 | 12 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 38 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 36 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 36 | suppressed |
| Pregabalin | Pregabalin | 35 | 14 |
| Buspirone Hcl | Buspirone Hcl | 33 | 12 |
| Metformin Hcl Er | Metformin Hcl | 31 | 14 |
| Atenolol | Atenolol | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 25 |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Sucralfate | Sucralfate | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | 11 |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 11 |
| Spiriva Respimat | Tiotropium Bromide | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 15 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Fluocinonide | Fluocinonide | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $33.95 · 2 records | GENZYME CORPORATION | DUPIXENT, TRELEGY ELLIPTA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error